John Cullity
Follow
Get notifications in MyBN when activity occurs.
John Cullity
Executive Chair / Race Oncology
After earning his medical degree (MBBS) from the University of Western Australia, Dr John Cullity undertook advanced training in haematology-oncology at QEII Medical Center. He then moved to the United Kingdom to complete Royal College of Physicians examinations. He also completed a Master of Science at the London School of Economics and an MBA at The Wharton School, University of Pennsylvania.
After a period consulting to World Health Organisation and The World Bank, Dr Cullity worked as a director of Health Economics (Oncology) & Strategic Pricing at Schering-Plough, and then for seven years at Sanofi-Aventis as director of Health Economics (Oncology), senior director and head of strategic pricing, and senior director of business development & licensing (Oncology).
Between 2010 and 2017 in New York, Dr Cullity was a principal for Torreya Partners, the internationally-recognised transactions firm where he managed numerous licensing/M&A transactions and participated in the establishment of several biotech companies. He remains a director of Theraly Fibrosis (spin-out from Johns Hopkins University), Haemalogix (Australian immune-oncology company) and Ceramedix Holdings (spin-out from Memorial Sloan Kettering Cancer Center).
After a period consulting to World Health Organisation and The World Bank, Dr Cullity worked as a director of Health Economics (Oncology) & Strategic Pricing at Schering-Plough, and then for seven years at Sanofi-Aventis as director of Health Economics (Oncology), senior director and head of strategic pricing, and senior director of business development & licensing (Oncology).
Between 2010 and 2017 in New York, Dr Cullity was a principal for Torreya Partners, the internationally-recognised transactions firm where he managed numerous licensing/M&A transactions and participated in the establishment of several biotech companies. He remains a director of Theraly Fibrosis (spin-out from Johns Hopkins University), Haemalogix (Australian immune-oncology company) and Ceramedix Holdings (spin-out from Memorial Sloan Kettering Cancer Center).
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1228th | Aeeris | -34% | 9% |
| 1596th | Magnetite Mines | -59% | 3% |
| 1622nd | Race Oncology | -60% | 60% |
| 1671st | Westar Resources | -65% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 905th |  | Race Oncology | $3.1m |
| 912th | | Aeeris | $3.0m |
| 1086th | | Magnetite Mines | $213k |
| 1090th | | Westar Resources | $196k |
| 1091st | | Tamboran Resources | $194k |
1328 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| REMUNERATION UPDATE: Executive Chair, Race Oncology | 03 Nov 2020 |
